Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:

DOP079

Predictors of first neoplastic colonic lesion in patients with inflammatory bowel disease undergoing colonoscopic surveillance

Authors:

J. Kirchgesner*1, M. Svrcek2, C. Landman1, A. Bourrier1, 
I. Nion-Larmurier1, H. Sokol1, J. Cosnes1, J.-F. Flejou2, L. Beaugerie1

1Saint-Antoine Hospital, AP-HP, Gastroenterology, Paris, France, 2Saint-Antoine Hospital, AP-HP, Pathology, Paris, France

DOP080

Final results of a randomised study comparing high-definition colonoscopy alone with high- definition dye spraying and electronic virtual chromoendoscopy using iSCAN for detection of colonic neoplastic lesions during IBD surveillance colonoscopy

Authors:

M. Iacucci*1, M. Fort Gasia1, A. Oluseyi1, R. Panaccione1, S. Gui X2, S. Urbanski3, P. Minoo3, S. Ghosh1

1University of Calgary, Gastroenterology, Calgary, Canada, 2University of Calgary, Pathology, Calgary, Canada, 3University of Calgary, Calgary, Canada

DOP081

Outcomes of colitis-associated dysplasia after referral from the community to a tertiary centre

Authors:

D. Rubin*, N. Krugliak Cleveland, D. Rodriquez

University of Chicago Medicine, Inflammatory Bowel Disease Centre, Chicago, Illinois, United States

DOP082

Proximity extension assay immunoassay technology identifies novel serum biomarkers that can diagnose and classify inflammatory bowel diseases: IBD Character Consortium

Authors:

R. Kalla*1, A. Ocklind2, C. Petrén2, N. Nordberg2, N. Kennedy1, N. Ventham1, E. Pettersson2, D. Bergemalm3, J. Lindström4, S. Vatn4, H. Hjortswang5, E. Nimmo1, H. Drummond1, P. Ricanek6, F. Dahl4, D. Wilson1, J. Jahnsen4, F. Gomollón7, M. Pierik8, J. Söderholm9, M. Vatn4, J. Halfvarson3, IBD Character Consortium1, J. Satsangi1

1University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, 2Olink, Bioscience, Uppsala, Sweden, 3Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden, 4Oslo University Hospital, Department of Gastroenterology, Oslo, Norway, 5Linköping University Hospital, Department of Gastroenterology, Linköping, Sweden, 6Akershus University Hospital, Deaprtment of Gastroenterology, Lorenskog, Norway, 7University of Zaragosa, Gastroenterology, Zaragosa, Spain, 8Maastricht University Medical Centre (MUMC), Department of Gastroenterology and Hepatology, Maastricht, Netherlands, 9Linköping University Hospital, Department of Surgery, Linköping, Sweden

DOP083

Faecal calprotectin improves the predictive power of 3 practical indices for mucosal healing amongst patients with Crohn’s disease: results from PREDICT

Authors:

W. Sandborn*1, R. Panaccione2, J.-F. Colombel3, E. Louis4, A. Robinson5, K. Wallace5, M. Bereswill6, M. Shapiro5, N. Chen5, M. Skup5, S. Wang5, R. Thakkar5, J. Chao5

1University of California, San Diego, La Jolla, California, United States, 2University of Calgary, Medicine, Calgary, Canada, 3Centre Hospitalier Universitaire de Lille, Lille, France, 4University of Liège, Liège, Belgium, 5AbbVie Inc., North Chicago, Illinois, United States, 6AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

DOP084

Identification of a potential new prognostic biomarker to select inflammatory bowel disease patients that fail standard therapy

Authors:

M. S. Pereira1, S. Campos1, A. M. Dias1, I. Pedroto2, C. A. Reis1, 3, L. Maia2, R. Marcos-Pinto2, 3, P. Lago2, S. S. Pinho*1, 3

1Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) & Institute for Research and Innovation in Health (i3S), Porto, Portugal, 2Centro Hospitalar do Porto, Department of Gastroenterology, Porto, Portugal, 3Institute of Biomedical Sciences of Abel Salazar (ICBAS), University of Porto, Porto, Portugal

DOP085

Ileocolonic involvement and diagnosis is related to fragments of the extracellular matrix measured in serum of patients with Crohn’s disease

Authors:

J. H. Mortensen*1, M. D. Jensen2, J. Kjeldsen2, A. Krag2, M. Karsdal1, A.-C. Bay-Jensen1

1Nordic Bioscience, Biomarkers & Research, Herlev, Denmark, 2Odense University Hospital, Department of Gastroenterology, Odense, Denmark

DOP086

Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases

Authors:

A. Buisson*1, 2, E. Vazeille1, 2, R. Minet Quinard3, M. Goutte1, 2, D. Bouvier3, F. Goutorbe1, B. Pereira4, N. Barnich2, G. Bommelaer1, 2

1University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France, 2UMR 1071 Inserm/Université d’Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France, 3University Hospital G. Montpied, Biochemistry laboratory, Clermont-Ferrand, France, 4GM – Clermont-Ferrand University and Medical Centre, Biostatistics Unit, Clermont-Ferrand, France

DOP087

MMP degraded type III collagen is a novel serological biomarker for penetrating (Montreal B3) Crohn’s disease

Authors:

W. T. van Haaften*1, 2, J. H. Mortensen3, M. A. Karsdal3, A.-C. Bay-Jensen3, G. Dijkstra2, P. Olinga1

1University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Groningen, Netherlands, 2University Medical Centre Groningen, Department of Gastro-enterology and Hepatology, Groningen, Netherlands, 3Nordic Bioscience, Biomarkers and Research, Herlev, Denmark

DOP088

Inflammatory biomarkers in serum discriminate Crohn’s disease and ulcerative colitis from healthy controls

Authors:

E. Andersson*1, D. Bergemalm1, R. Kruse1, M. D’Amato2, D. Repsilber1, J. Halfvarson1

1Örebro University, Faculty of Medicine and Health, Örebro, Sweden, 2Karolinska Institutet, Department of Medicine, Solna, Sweden

DOP089

Microbiota profiles in treatment-naïve Norwegian IBD and non-IBD patients: part of the European Union IBD character consortium

Authors:

P. Ricanek*1, S. Vatn1, T. Lindahl2, E. Ciemniejewska2, J. Jahnsen1, C. Casen2, M. H. Vatn1

1Akershus University Hospital, Department of Gastroenterology, Lørenskog/Nordbyhagen, Norway, 2Genetic Analysis AS, Oslo, Norway

DOP090

The role of the microbiome in clinical response to golimumab in ulcerative colitis

Authors:

C. Monast*, S. Telesco, K. Li, K. Hayden, C. Brodmerkel

Janssen R & D, LLC, Spring House, Pennsylvania, United States

N001

Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study

Authors:

U. Chauhan*1, D. Armstrong2, S.L. Halder2, J. K. Marshall2, F. Tse2, M. I. Pinto Sanchez2, Y. Farbod2, J. Popov2, S. Kaasalainen3, P. Moayyedi2

1McMaster University Medical Centre, Digestive Disease, Hamilton, Canada, 2McMaster University, Department of Gastroenterology, Hamilton, Canada, 3McMaster University, School Of Nursing, Hamilton, Canada

N002

What are the factors related to depression in patients with ulcerative colitis in Japan?

Authors:

A. Kawakami*1, M. Tanaka2, N. Yamamoto-Mitani3, M. Naganuma4, S. Maeda5, R. Kunisaki1

1Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan, 2Mahidol University, Faculty of Medicine Ramathibodi Hospital, Ramathibodi School of Nursing, Bangkok, Thailand, 3The University of Tokyo, School of Health Sciences and Nursing, Tokyo, Japan, 4Keio University, Division of Gastroenterology and Hepatology, Tokyo, Japan, 5Yokohama City University Graduate School of Medicine, Department of Gastroenterology, Yokohama, Japan

N003

Sexual dysfunction assessment in inflammatory bowel diseases patients

Authors:

J. Barros1, R. Saad-Hossne*2, L. Sassaki3, J. Baima3, M. Dorna3, C. Sibia1, F. Renosto1, R. Silva1, E. Farineli1, R. Biondi1

1Paulista State University - Botucatu Medical School, Botucatu, Brazil, 2Paulista State University - Botucatu Medical School, GI Surgery, Botucatu, Brazil, 3Paulista State University - Botucatu Medical School, Gastroenterology, Botucatu, Brazil

N004

Faecal Incontinence in inflammatory bowel disease and its association with anxiety and depression in an Irish tertiary centre

Authors:

A. Keogh*

University Hospital Galway, Galway, Ireland

N005

Adherence to outpatient follow-up visit in inflammatory bowel disease patients

Authors:

M.G. Vettorato*, G. Lorenzon, S. Bellia, A. Rigo, O. Bartolo, G. Girardin, F. Simonetti, R. D’Incà, G. C. Sturniolo, E. V. Savarino

University of Padua, Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy, Padua, Italy

N006

Exploring fatigue in inflammatory bowel disease: a descriptive phenomenological study

Authors:

W. Czuber-Dochan*1, J. Armes1, E. Ream2, C. Norton1

1King’s College London, Florence Nightingale Faculty of Nursing & Midwifery, London, United Kingdom, 2University of Surrey, Faculty of Health and Medical Sciences, Guildford, United Kingdom

N007

Effects of introduction of an inflammatory bowel diseases nurse position on the quality of delivered care

Authors:

S. Coenen*, E. Weyts, S. Vermeire, M. Ferrante, M. Noman, V. Ballet, G. Van Assche

UZ Leuven, Gastroenterology, Leuven, Belgium

N008

Reasons for consultation of patients with inflammatory bowel disease in telephone helplines attended by nurses

Authors:

E. Navarro Correal*1, O. Benítez Leiva2, A. Dosal Galguera3, M. Gallego Barrero4, F. Murciano Gonzalo5, E. Sánchez Pastor6

1Vall d’Hebron university Hospital, Gastroenterology, Barcelona, Spain, 2Hospital Mútua de Terrassa2, Gastroenterology, Terrassa, Spain, 3Univesitaria Parc Taulí Health Corporation, Gastroenterology, Sabadell, Spain, 4Hospital Clínic Barcelona, Gastroenterology, Barcelona, Spain, 5Hospital del Mar, Gastroenterology, Barcelona, Spain, 6Bellvitge University Hospital, Gastroenterology, Hospitalet de LLobregat, Spain